Articles about Ribon Therapeutics

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study - The Lancet Digital Health

License to Pill: Biotech and pharma deals from Jan. 30-Feb. 12

Molecules, Free Full-Text

Articles about Ribon Therapeutics

Sally Johnson - Chief People Officer - Ribon Therapeutics

Kevin Kuntz - Chief Drug Development Officer - Ribon Therapeutics

Articles about Ribon Therapeutics

Our Targets – Ribon Therapeutics

Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Leadership – Ribon Therapeutics

Ribon Therapeutics

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials - ScienceDirect